Pharmaron Beijing Co., Ltd. (HKG:3759)

Market Cap	52.53B +14.6%
Revenue (ttm)	14.80B +14.8%
Net Income	1.65B -19.7%
EPS	0.94 -19.4%
Shares Out	n/a
PE Ratio	31.78
Forward PE	21.79
Dividend	0.22 (1.16%)
Ex-Dividend Date	Jul 4, 2025

Volume	4,061,140
Average Volume	4,570,618
Open	18.02
Previous Close	18.19
Day's Range	18.02 - 19.11
52-Week Range	10.46 - 30.12
Beta	1.14
RSI	42.64
Earnings Date	Mar 31, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotide...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 21,370
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3759

Financial Performance

In 2024, Pharmaron Beijing's revenue was 12.28 billion, an increase of 6.39% compared to the previous year's 11.54 billion. Earnings were 1.79 billion, an increase of 12.01%.

Financial numbers in CNY